Trans-AUCB is primarily utilized in research settings as a potent and selective inhibitor of soluble epoxide hydrolase (sEH). This enzyme plays a significant role in the metabolism of epoxy fatty acids, which are involved in various physiological processes, including inflammation and cardiovascular regulation. By inhibiting sEH, trans-AUCB helps to increase the levels of these beneficial epoxy fatty acids, thereby potentially reducing inflammation and offering protective effects against conditions such as hypertension, pain, and atherosclerosis. Its application is particularly valuable in preclinical studies aimed at understanding the therapeutic potential of sEH inhibition in treating inflammatory and cardiovascular diseases. Researchers also use trans-AUCB to explore its effects on other conditions linked to sEH activity, such as diabetes and neurodegenerative disorders.